✦ LIBER ✦

Pilot study of cyclophosphamide-doxorubicin-vincristine-cisplatin-etoposide hybrid chemotherapy in small cell lung cancer

✍ Scribed by Taisuke Ohnoshi; Shunkichi Hiraki; Hiroshi Ueoka; Katsuyuki Kiura; Haruhito Kamei; Takashi Horiguchi; Tsuyoshi Kodani; Tadashi Maeda; Masahiro Tabata; Takuo Shibayama; Yoshihiko Segawa; Kazuyo Miyatake; Nagio Takigawa; Ikuro Kimura

Publisher: John Wiley and Sons
Year: 1993
Tongue: English
Weight: 508 KB
Volume: 72
Category: Article
ISSN: 0008-543X
DOI: 10.1002/1097-0142(19930901)72:5<1597::aid-cncr2820720517>3.0.co;2-n

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Weekly doxorubicin versus doxorubicin ev

Weekly doxorubicin versus doxorubicin every 3 weeks in cyclophosphamide, doxorubicin, and cisplatin chemotherapy for non-small cell lung cancer

✍ Theera Umsawasdi; Manuel Valdivieso; Daniel J. Booser; H. Thomas Barkley Jr; Mic 📂 Article 📅 1989 🏛 John Wiley and Sons 🌐 English ⚖ 579 KB

The addition of cisplatin to cyclophosph

The addition of cisplatin to cyclophosphamide-doxorubicin-etoposide combination chemotherapy in the treatment of patients with small cell lung carcinoma : A randomized study of 457 patients

✍ Thierry Urban; Claude Chastang; François-Xavier Lebas; Jean-Paul Duhamel; Guy Ad 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 94 KB 👁 2 views

## BACKGROUND. To assess whether the addition of cisplatin (100 mg/m 2 administered intravenously on Day 1) to CDE (cyclophosphamide [1000 mg/m 2 on Day 1], doxorubicin [45 mg/m 2 on Day 1], and etoposide [150 mg/m 2 on Days 1 and 2] combination is useful in the treatment of patients with small cel

Comparison of etoposide and cisplatin wi

Comparison of etoposide and cisplatin with bis-chloro-ethylnitrosourea, thiotepa, vincristine, and cyclophosphamide for salvage treatment in small cell lung cancer. A Southwest Oncology Group Study

✍ ROBERT M. O'Bryan; John J. Crowley; Paik N. Kim; Robert B. Epstein; Barbara Neil 📂 Article 📅 1990 🏛 John Wiley and Sons 🌐 English ⚖ 447 KB 👁 2 views

Cisplatin, etoposide, and mitomycin in t

Cisplatin, etoposide, and mitomycin in the treatment of non-small cell carcinoma of the lung. A pilot study

✍ Stephen Davis; Maurizio Tomato; Lucio Crino; Mari Antonetta Colozza; Kenneth Lub 📂 Article 📅 1986 🏛 John Wiley and Sons 🌐 English ⚖ 192 KB 👁 2 views

A total of 39 patients with non-small cell carcinoma of the lung (NSCL) were treated with cisplatin, etoposide, and mitomycin. A major response rate (complete response + partial response) was seen in 15 patients (39%). Median survival for all patients was 340 days; median survival of the responding

A phase II study of methotrexate, doxoru

A phase II study of methotrexate, doxorubicin, cyclophosphamide, and lomustine chemotherapy and lonidamine in advanced non-small cell lung cancer

✍ Gianfranco Buccheri; D. Ferrigno; A. Rosso 📂 Article 📅 1993 🏛 John Wiley and Sons 🌐 English ⚖ 826 KB

Combination chemotherapy with adriamycin

Combination chemotherapy with adriamycin, etoposide, and cyclophosphamide for small cell carcinoma of the lung. A study by the EORTC lung cancer working party (Belgium)

✍ J. Klastersky; J. P. Sculier; J. P. Dumont; D. Becquart; G. Vandermoten; P. Rocm 📂 Article 📅 1985 🏛 John Wiley and Sons 🌐 English ⚖ 425 KB 👁 2 views